Research advances in mechanism of acquired resistance to EGFR-TKIs in non-small cell lung cancer

As the main pathological type of lung cancer, non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer, and threatens human health seriously. The rapid development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has benefited thousands of the patients with NSCLC. Unfortunately, acquired resistance to EGFR TKIs is inevitable, eventually resulting in disease progression, recurrence and death. This review focuses on the latest research advances in the mechanism of acquired resistance to EGFR-TKIs in patients with NSCLC.